Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00578916

Enrollment

Registered

2007-12-21

Start date

2008-01-31

Completion date

2008-01-31

Last updated

2008-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.

Interventions

DRUGEVRI (BMS-690514)

Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male subjects * Body mass index (BMS) of 18 - 30 kg/m², inclusive

Exclusion criteria

* Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years

Design outcomes

Primary

Measure	Time frame
Single dose pharmacokinetics of BMS-690514 and radioactivity in plasma and urine	measured for 10 days post-dose

Secondary

Measure	Time frame
Determination of biotransformation profiles and recorded adverse events	for 10 days post-dose

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026